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Abstract: In recent years, first evidences emerged that sympathetic neurotransmitters influence
osteoarthritis (OA) manifestation. Joint-resident stem cells might contribute to cartilage repair,
however, their chondrogenic function is reduced. The neurotransmitter norepinephrine (NE) was
detected in the synovial fluid of trauma and OA patients. Therefore, the aim of this study was to
analyse how NE influences the chondrogenesis of synovial adipose tissue-derived stem cells (sASCs).
sASCs were isolated from knee-OA patients synovia. After adrenoceptor (AR) expression analysis,
proliferation and chondrogenic differentiation in presence of NE and/or α- and β-AR antagonist
were investigated. Cell count, viability, chondrogenic and hypertophic gene expression, sulfated
glycosaminoglycan (sGAG) and type II collagen content were determined. Key AR-dependent
signaling (ERK1/2, PKA) was analyzed via western blot. sASC expressed α1A-, α1B-, α2A-, α2B-,
α2C-, and β2-AR in monolayer and pellet culture. NE did not affect proliferation and viability,
but 10−7 and 10−6 M NE significantly reduced sGAG and type II collagen content as well as ERK1/2
phosphorylation. These effects were fully reversed by yohimbine (α2-AR antagonist). Our study
confirms the important role of NE in sASC chondrogenic function and provides new insights in
OA pathophysiology. Future studies might help to develop novel therapeutic options targeting
neuroendocrine pathways for OA treatment.
Keywords: synovial adipose stem cells; sympathicus; norepinephrine; adrenoceptors; chondrogenesis;
osteoarthritis; physioxia
1. Introduction
Osteoarthritis (OA) is the most common degenerative joint disorder affecting about 10% of the
global population [1]. OA is characterized by progressive degradation of articular cartilage [2] leading
to pain, stiffness, and disabilities. There is no proven treatment for OA at present, therapies target late
stage pain or inflammation, but in most cases prosthetic joint replacement remains as final therapy
option [3]. OA pathogenesis involves the interaction of cartilage-surrounding joint tissues including
synovial tissue, bone, ligaments, meniscus, and the synovial fluid [4–6]. Since articular cartilage is
avascular, aneural, and alymphatic chondrocytes exhibit a very limited self-regenerative capacity [7].
However, during the past decades, the existence of highly regenerative mesenchymal stem cells (MSCs)
was confirmed in cartilage-surrounding tissues including synovium, bone marrow, and synovial
fluid [8,9]. These cells might migrate to damaged cartilage areas and differentiate to chondrocytes [9].
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There is strong evidence that synovial adipose tissue-derived MSCs (sASC) contribute to the
repair of cartilage injuries [10,11]. However, the chondrogenic capacity of MSCs detected in OA
cartilage is insufficient [10] and the reasons for this are not completely understood. Recent studies
demonstrated that peripheral sympathetic nerve fibers are involved in chondrogenic extracellular
matrix (ECM) deposition during endochondral ossification [12–14]. Furthermore, sympathetic nerve
fibers expressing tyrosine hydroxylase (TH), which is the key enzyme of catecholamine biosynthesis,
have been detected in healthy and OA joint tissues [15–17]. TH-positive nerve fibers release high
concentrations of norepinephrine (NE) into the synovial fluid as shown in previous studies [18].
NE is one major catecholaminergic neurotransmitter of the sympathetic nervous system and binds
to specific adrenergic receptors (AR) depending on its concentration [19,20]. All α and β adrenergic
receptors subtypes (α1A,α1B,α1D,α2A,α2B,α2C,β1,β2,β3) belong to the G protein-coupled receptor
family. Depending on the activation of alpha subunits of ARs (Gs, Gi, or Gq), different intracellular
signaling pathways become activated [21]. At low concentrations (≤10−7 M), NE mainly acts via α-ARs
with subsequent protein kinase a (PKA) and cAMP inhibition (Gαi signaling). In contrast, NE at
high concentrations (≥10−7 M) preferentially acts via β-ARs leading to PKA and cAMP increase (Gαi
signaling). Furthermore, β-arrestin regulates AR-mediated signaling by binding to phosphorylated
ARs which in turn leads to the alternative ERK1/2 pathway [22–24]. Previous studies investigated the
effects of NE on articular cartilage and described that NE induced catabolic effects in chondrocytes
by inhibiting type II collagen synthesis via β2-AR or accelerated cartilage ECM degradation via
α2A-AR suggesting that mainly the α2A- and β2-AR subtypes might play a role in disturbed cartilage
regeneration during OA development [25–27]. Recently, we demonstrated that bone marrow-derived
MSCs (BMSCs) obtained from trauma patients express α- and β-ARs [18] and that NE inhibits
chondrogenic differentiation with concomitant induction of hypertrophy by the β2-AR under normoxic
conditions (20% O2) [18]. However, no studies using sASC regarding NE sensitivity and chondrogenic
potential under NE influence have been performed until now. Furthermore, most existing studies
on the regeneration potential of MSCs have been performed under normoxia, although cartilage
microenvironment contains only about 2% O2 representing the “physioxic condition” [28,29]. Therefore,
the aim of the present study was to address the effect of NE on sASC proliferation and chondrogenic
differentiation under physioxic conditions.
2. Results
2.1. Stem Cell-Specific Surface Markers and Chondrogenic Differentiation Potential of ASCs
Stem cell-specific surface markers of ASCs were investigated by FACS analysis of CD11b, CD19,
CD34, and HLA-DR. More than 90% of the ASCs were positive for CD73, CD90, and CD105 as well as
negative for HLA-DR, CD11b, CD19, CD34, and CD45 as suggested by The Mesenchymal and Tissue
Stem Cell Committee of the International Society for Cellular Therapy [28] (Figure 1A,B).
The macroscopic observation revealed a well-condensated nodular morphology with increasing
pellet size from day 1 until day 21 and the histological analysis by the metachromatic DMMB staining
confirmed a characteristic and increasing sGAG deposition during 21 days of chondrogenesis. Similarly,
type II collagen staining intensity steadily increased from day 1 to day 21 (Figure 1C). Expression of
SOX9 and COL2A1, the two major marker genes indicative of chondrogenic differentiation, increased
significantly from day 1 until day 21 (both SOX9 (~4-times) and COL2A1 (~104-times) day 21 to day 1
p = 0.008; Figure 1D).
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Figure 1. Analysis of mesenchymal stem cells (MSC)-specific surface markers and chondrogenic 
differentiation capacity of synovial adipose tissue-derived MSCs (sASC) obtained from osteoarthritis 
(OA) patients. (A) Human sASCs derived from OA patients were positive for CD73, CD90, and 
CD105 and were negative for CD11b, CD19, CD34, CD45 and human leukocyte antigen–DR isotype 
(HLA-DR) using FACS analysis (blue line—unstained negative control, green line—isotype control, 
red line—the target surface marker). (B) Quantification of MSC-specific marker expression on sASCs 
from eight different OA patients (n = 8). Data are presented as box plots with the 10th, 25th, 50th 
(median), 75th, and 90th percentiles. Each black circle represents an individual patient: (C) 
Macroscopic, histologic (sGAG) and immunohistochemical (type II collagen) analysis of untreated 
chondrogenic sASC pellets at day1, day 7, day 14, and day 21 of differentiation (bars, 500 μm). (D) 
Relative gene expression of SOX9 and type II collagen in untreated ASC pellets after 21 days of 
chondrogenesis. Data are presented as box plots with the 10th, 25th, 50th (median), 75th, and 90th 
percentiles. Each black circle represents an individual patient (n = 5–6). Significant p-values against 
untreated control are presented as ** = p < 0.01. 
2.2. AR Expression Profile of ASCs in Monolayer and Pellet Cultures 
First, the expression of different AR subtypes was screened by RT-PCR. Monolayer ASCs 
expressed α1B, α2A-, α2B-, α2C-, and β2-AR. Gene expression levels of α2C- and β2-AR were the 
highest. The receptors α1B-AR, α2A-AR, and α2B-AR were moderately expressed. The receptors 
α1A-, α1D-, β1-AR and TH could not be detected (Figure 2A). Chondrogenic sASCs in pellets 
expressed α1A-, α1B-, α2A-, α2B-, α2C-, β1-and β2-AR, at day 1 and also at day 21 of 
chondrogenesis (Figure 2B,C). The average gene expression level of these ARs was similar at both 
time points except for strongly increasing α1A-AR expression from day 1 until day 21. The ARS 
α1D-AR, β3-AR and TH were not detectable at the gene expression level (Figure 2B,C). Next, the two 
most prominent ARs with opposing downstream signaling pathways, α2A-AR and β2-AR, were 
stained immunohistochemically in order to confirm their expression also at the functional protein 
level. Both, α2A-AR and β2-AR were detected at each time point during chondrogenesis (day 1, 7, 
14, and 21) (Figure 3A). No age-, gender-, or medication-dependent differences were observed 
regarding AR expression neither in monolayer nor in pellet cultures. Furthermore, NE stability in 
the cell culture medium over 24 h was tested in order to clarify which NE concentration is present or 
might act during chondrogenesis with media change every other day. After one day in the 
i re 1. alysis f ese c al ste cells ( S )-s ecific s rface ar ers a c r e ic
iffere ti ti c cit f s i l i se tiss e- eri e s (s ) t i e fr ste rt ritis
( ) atients. (A) Human sASCs derived from OA patients were positive for CD73, CD90, and CD105
and were negative for CD11b, 19, CD34, CD45 and hum leukocyte antigen–DR isotype (HLA-DR)
using FACS analysis (blue line—unstained negative control, green line—isotype control, red line—the
target surface marker). (B) Quantification of MSC-specific marker expression on sASCs from eight
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repr sents an individual patient (n = 5–6). Significant p-v lues against untreated control re presented
as ** = p < 0.01.
2.2. AR Expression Profile of ASCs in Monolayer and Pellet Cultures
First, the expression of different AR subtypes was screened by RT-PCR. Monolayer ASCs
expressed α1B, α2A-, α2B-, α2C-, and β2-AR. Gene expression levels of α2C- and β2-AR were the
highest. The receptors α1B-AR, α2A-AR, and α2B-AR were moderately expressed. The receptors α1A-,
α1D-, β1-AR and TH could not be detected (Figure 2A). Chondrogenic sASCs in pellets expressed α1A-,
α1B-, α2A-, α2B-, α2C-, β1-and β2-AR, at day 1 and also at day 21 of chondrogenesis (Figure 2B,C).
The average gene expression level of these ARs was similar at both time points except for strongly
increasing α1A-AR expression from day 1 until day 21. The ARS α1D-AR, β3-AR and TH were
not detectable at the gene expression level (Figure 2B,C). Next, the two most prominent ARs with
opposing downstream signaling pathways, α2A-AR and β2-AR, were stained immunohistochemically
in order to confirm their expression also at the functional protein level. Both, α2A-AR and β2-AR were
detected at each time point during chondrogenesis (day 1, 7, 14, and 21) (Figure 3A). No age-, gender-,
or medication-dependent differences were observed regarding AR expression neither in monolayer
nor in pellet cultures. Furthermore, NE stability in the cell culture medium over 24 h was tested in
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order to clarify which NE concentration is present or might act during chondrogenesis with media
change every other day. After one day in the incubator, about 40–50% of the initial NE concentration
was measurable, which was independent of the applied GSH amount (Supplementary Figure S1).
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Figure 2. Adrenoceptor (AR) and tyrosine hydroxylase (TH) gene expression of sASCs in monolayer 
and pellet cultures (A) RT-PCR of AR and TH gene expression profile in untreated sASC in 
monolayer culture and average score of AR and TH gene expression in sASCs from three different 
OA patients. (n = 3, mean ± standard deviation). (B) AR and TH gene expression profile in untreated 
sASC in three-dimensional chondrogenic pellet culture at day 1 and average score of AR and TH 
gene expression in sASCs from four different OA patients. (n = 4, mean ± standard deviation). (C) AR 
and TH gene expression profile in untreated sASC in three-dimensional chondrogenic pellet culture 
at day 21 of differentiation and average score of AR and TH gene expression in sASCs from four 
different OA patients. (n = 4, mean ± standard deviation). 
2.3. NE-Mediated Intracellular Signaling 
Western Blot analyses of monolayer sASCs revealed that NE treatment results in ERK1/2 
phosphorylation. Both, 10−8 and 10−6 M NE concentrations activated the ERK1/2 pathway already 
after 15 min (Figure 3B). Furthermore, while the ERK1/2 phosphorylation increased 
dose-dependently by NE treatment (p = 0.02 for NE 10−6 M), the PKA pathway was not activated 
(Supplementary Figure S2). 
i r . r t r ( ) t r i r l ( ) r i f i l r
pellet cultures (A) RT-PCR of AR and TH gene expression profile in untr ated sASC in monolayer
culture and average score of AR and TH gene expressio in sASCs from three different OA patients.
(n = 3, mean ± standard deviation). (B) AR and TH gene expression profile i untreated sASC in
three-dimensional chondrogenic pellet culture at day 1 and verage score of AR and TH gene expression
in sASCs from four different OA patients. (n = 4, mea ± standard deviation). (C) AR and TH gene
expression profile in untreated sASC in three-dime sional chondrogeni pellet culture at day 21 of
differentiation and average score of AR and TH gene expression in sASCs from four different OA
pati nts. (n = 4, mean ± standard deviation).
2.3. NE-Mediated Intracellular Signaling
Western Blot analyses of monolayer sASCs revealed that NE treatment results in ERK1/2
phosphorylation. Both, 10−8 and 10−6 M NE concentrations activated the ERK1/2 pathway already after
15 min (Figure 3B). Furthermore, while the ERK1/2 phosphorylation increased dose-dependently by
NE treatment (p = 0.02 for NE 10−6 M), the PKA pathway was not activated (Supplementary Figure S2).
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Figure 3. AR protein expression during sASC chondrogenesis and norepinephrine (NE)-mediated 
activation of intracellular signaling. (A) Immunohistochemical analysis of β2-AR and α2a-AR during 
sASC chondrogenesis on days 1, 7, 14, and 21 of differentiation (bars, 500 μm in upper panels and 50 
μm in lower panels). (B) Western blot analysis of total ERK1/2 as well as ERK1/2 phosphorylation in 
chondrogenic sASC culture in the absence or presence of NE (10−8 M and 10−6 M, representative blot 
of one OA patient). 
2.4. Effect of NE on ASC Proliferation 
The sACSs were treated for seven days with NE (10−9–10−6 M). When compared to the untreated 
control group, treatment with NE at different concentrations had no significant effect on the cell 
count. Also the number of dead cells was not influenced by NE (Figure 4). Similarly, measurement of 
ASC viability after NE treatment by LDH-assay revealed no changes compared to control 
(Supplementary Figure S3A). 
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s S chondrogenesis on days 1, 7, 14, and 21 of differentiation (bars, 500 µm in upper panels and
50 µm in lower panels). (B) Western blot analysis of total ERK1/2 as well as ERK1/2 phosphorylation in
chon rogenic s S culture in the absence or presence of NE (10−8 an 10 , representative blot
f e atie t).
2.4. Effect of E on ASC Proliferation
The s CSs ere treated for seven days ith NE (10−9–10−6 M). hen co pared to the untreated
control group, treatment with NE at different concentrations had no significant effect on the cell count.
Also the number of dead cells was not influenced by NE (Figure 4). Similarly, measurement of ASC
viability after NE treatment by LDH-assay revealed no changes compared to control (Supplementary
Figure S3A).
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Figure 4. Proliferation capacity of sASCs in presence of NE in different concentrations (10−9–10−6 M).
The white boxes represent the total number of cells, the red boxes represent the number of dead cells
after seven days. Data are presented as box plots, where the boxes represent the 25th to 75th percentiles,
the lines within the boxes represent the median, and the lines outside the boxes represent the 10th and
90th percentiles (untreated control = 100%, broken line). Each black circle represents an individual
patient (n = 8).
2.5. Effects of NE on sASC Chondrogenesis
NE concentrations used had no proliferative, cytotoxic, or apoptotic effects during chondrogenesis
as reflected by LDH measurements and dsDNA quantification (Supplementary Figure S3B,C).
The morphological examination revealed that chondrogenic pellets treated with NE (10−9–10−6 M)
were smaller than untreated pellets at day 21 (Figure 5A). This observation was confirmed by the
calculation of pellet volumina: the pellet volume at day 21 was significantly reduced after incubation
with 10−6 M (p < 0.001) as well as with 10−7 M NE (p = 0.007) (Figure 5B).
The reduction in pellet volume was accompanied by less blue-to-purple color change of the
metachromatic dye DMMB, indicating a lower amount of sGAGs in NE-treated pellets (Figure 5A).
The biochemical quantification confirmed this observation, because 10−7 and 10−6 M NE treatment
resulted in significantly lower sGAG concentrations compared to untreated control group (Figure 5B;
p = 0.04 for 10−7 M NE and p = 0.006 for 10−6 M NE). In addition, type II collagen staining intensity was
reduced in NE-treated pellets at day 21 as shown by immunohistochemistry (Figure 5A). This finding
was confirmed by type II collagen ELISA showing significantly reduced type II collagen amounts in
pellets after incubation with 10−7 (p = 0.02) and 10−6 M (p = 0.009) NE (Figure 5B). The observed effects
on pellet size and ECM deposition became apparent first after day 14 of chondrogenesis. At day 7 or
14, no differences between treated and untreated groups were detected (Supplementary Figure S4).
In addition, in order to explore effects on fibrocartilaginous (COL1A1) and hypertrophic (COL10A1,
RUNX2, MMP13) differentiation and ECM degeneration specific marker genes were analyzed. However,
none of these genes was significantly influenced by NE treatment after 21 days (Supplementary Figure
S5). Regarding sACS chondrogenesis under NE influence, no influence of age, gender, and medication
was detected.
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2.6. Reversal of NE-Mediated Effects by Specific AR Antagonists 
Figure 5. Effect of ondrogenesis. (A) Macroscopic, and histologic (s AG) analy is
as well as i munohistochemical type II collagen staining of treated -t t ( 9–10−6 M)
chondrogenic sASC pell ts at day 21 of differentiation (bars 500 µm). (B) Quantific tion of pellet volume
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per patient (n = 6–10). Values are the percent of control (control = 100%, dashed line). Box plots
are explained in legend to Figure 1. Significant p-values against untreated control are presented as
* p < 0.05, ** p < 0.01, *** p < 0.001.
2.6. Reversal of NE-Mediated Effects by Specific i
To analyze which AR subtypes are responsible for the observed effects of NE, sASC pellets
were treated with specific AR antagonists or with NE (10−6 M) in combination with antagonists.
The treatment with NE in combination with antagonists or with antagonists alone had no proliferative,
cytotoxic, or apoptotic effects during chondrogenesis as reflected by LDH measurements and dsDNA
quantification (Supplementary Figure S7A,B).
The macroscopic and histological analyses revealed that the α2-AR antagonist yohimbine is able
to reverse the effects of NE on pellet size and partly on type II collagen synthesis, while no effects
on sGAG staining were observed by any treatment (Figure 6A). The reversing effects of yohimbine
on NE-mediated reduction of pellet size and type II collagen protein amount were confirmed by
quantification of pellet volumina and by type II collagen protein ELISA (Figure 6B; pellet volume:
p < 0.001 for NE 10−6 M vs. control, p = 0.04 for p vs. control, p = 0.034 for NE 10−6 M vs. Y; sGAG:
p = 0.04 for NE 10−6 M vs. control, p = 0.048 for D vs. control; type II collagen: p = 0.028 for NE 10−6 M
vs. control, p = 0.028 for D vs. control, p = 0.04 for NE 10−6 M vs. Y).
In contrast, the α1-AR and β2-AR antagonists (doxazosin and propranolol) were not able to
modulate the observed NE-mediated effects on pellet size or on type II collagen deposition and none of
the antagonists could significantly reverse the inhibitory effect of NE on sGAG (Figure 6A,B). Analysis
of the ERK1/2 pathway by western blot confirmed the involvement of α2-AR in the NE-mediated
effects, because the α2-AR antagonist yohimbine reversed the NE-induced phosphorylation of ERK1/2
(Figure 6C). The β2-AR antagonist propranolol only partly reversed ERK1/2 phosphorylation.
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histologic (sGAG) analysis and immunohistochemical type II collagen staining of chondrogenic sASC
pellets treated with NE (10−6 M) or ith plus specific AR antagonists at day 21 of differentiation
(bars 500 µm). (B) Quantification of pellet volume and biochemical quantification of type II collagen
and sGAG content of chondrogenic sASC pellets treated with NE (10−6 M) or with NE plus specific
AR antagonists at day 21. Each circle shows the mean of 3 repli ates per patient (n = 6–10). Values
ar the p rcent of control (control = 100%, dashed line). Significant p-values against untreated control
are presented as * p < 0.05, *** p < 0.001; # p < 0.05 to NE-treatment. (C) Western blot analysis of total
ERK1/2 and ERK1/2 pho ph ryla ion in of cho rogenic sASC pellets treated with NE (10−6 M) or with
NE plus specific AR antagonists: representative blot of one OA patient. Abb viatio s: D—doxazosin,
Y—yohimbine, P—propranolol.
3. Discussion
Cartilage injuries as well as OA-associated cartilage degeneration still represent a huge orthopedic
challenge [30]. Joint resident MSCs have been shown to be involved in cartilage regeneration
processes [31], however, these MSCs exhibit an insufficient chondrogenic potential, although their
Int. J. Mol. Sci. 2019, 20, 3127 9 of 17
number is increased in OA articular cartilage tissue [32]. The reasons for this contradictory phenomenon
are not completely understood. Recent studies demonstrated that TH-positive nerve fibers are
present in trauma and OA synovium [16,33]. Moreover, a considerable amount of the sympathetic
neurotransmitter NE was detected in synovial fluid samples of trauma and OA patients [18],
which might influence the regenerative capacity of the stem cells migrating from the synovial tissue
to damaged cartilage areas [9]. The present study is the first demonstrating noradrenergic effects on
sASC chondrogenesis and accordingly on articular cartilage homeostasis under physioxic conditions.
The initial step of this study was to confirm the molecular MSC characteristics of the isolated
sASCs. Analysis of multiple independent samples over months indicated that our isolation and cell
culture method resulted in homogenous sASC populations expressing the MSC-specific surface marker
panel [34]. Next, the chondrogenic differentiation capacity of sASCs derived from late OA patients
was analyzed. We demonstrated in this study for the first time that these sASCs condensated to typical
chondrogenic pellets and synthesized considerable amounts of cartilage-specific ECM over 21 days
under physioxia.
Another important prerequisite for the present study investigating the effects of NE on sASCs
function was the analysis of the complete AR profile of these cells. We could show for the first time that
sASCs expressed α1B, α2A-, α2B-, α2C-, and β2-AR. Kotova et al. also detected α1B, α2A-, and β2-AR,
but not α2B- and α2C on abdominal subcutaneous adipose tissue-derived MSCs [35]. Interestingly,
in the same tissue but in another studyα1A,α1B-, α2A-, α2B-, andβ1-AR were strongly butβ2-AR only
weakly expressed at mRNA and protein level [36]. One possible reason for this apparent discrepancy
might be the tissue-specific expression of different AR subtypes. In addition, the pathophysiological
situation caused by a catabolic microenvironment with increased NE concentrations might influence
the expression level of ARs [36,37]. However, it was not possible to compare our sASCs derived
from OA patients with ASCs from healthy or knee trauma donors, first, because healthy synovial
samples were not available and second, because in most cases neither healthy nor knee trauma
synovial tissue samples are surrounded or overgrown by adipose tissue in a similar manner to the
OA synovium. In order to consider possible autocrine effects, the expression of TH, the key enzyme
of catecholamine biosynthesis, was analyzed in sACSs. However, TH expression was not detectable,
neither in monolayer nor in chondrogenic sASC cultures. Thus, autocrine effects can be excluded.
This result is in line with our previous study demonstrating that BMSCs derived from knee trauma
patients are TH-negative [18]. The expression of ARs during chondrogenesis was also an important
point in this study. At the mRNA level α2A-, α2B-, and β2-AR were strongly expressed both at the
beginning and at the end of differentiation enabling NE to unfold its effects continuously over 21
days, while α1A-, α1B-, α2C-, and β1-AR expression was lower suggesting that chondrogenesis itself
does not influence AR expression. A similar AR expression profile in OA articular chondrocytes was
recently described by Speichert et al. and by Lorenz et al. [26,37] indicating that the AR profile of cells
from the same embryonal mesodermal origin might be conserved [38]. After detecting the major ARs,
we demonstrated that these receptors activate the downstream intracellular ERK1/2 signaling pathway,
without influencing the alternative PKA pathway, which is in line with previous studies investigating
murine chondrocytes under NE influence [25].
Even though sASCs express different ARs, NE had no effect on the proliferation and also their
viability was not influenced indicating that even highly-concentrated NE is not toxic to sASCs.
One possible explanation for proliferative non-responsiveness of sASCs to NE might be the immediate
vicinity to a catabolic and inflammatory microenvironment in the OA-affected joint. A similar
non-responsiveness to NE was also observed by Lorenz et al. in monolayer OA chondrocyte
proliferation experiments [26,39].
The relationship between NE concentration and chondrogenesis was investigated as a next
step. These experiments revealed a clear inhibition of chondrogenesis when NE was added in high
concentrations suggesting the involvement of β-ARs. We observed that pellets treated with NE
were smaller in size. For this reduction of pellet size different processes can be responsible: First,
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cell apoptosis could result in smaller pellets. However, we demonstrated that cell viability was
not affected by any treatment as indicated by an unchanged LDH activity. Furthermore, the cell
number was constant in all pellets reflected by equal dsDNA content. Second, the pellet size might
be reduced as a result of suppressed ECM synthesis and indeed, we evidenced significantly lower
sGAG and type II collagen concentrations in pellets treated with NE. This finding is in line with earlier
studies demonstrating decreased sGAG and type II collagen synthesis during BMSC or chondrocyte
differentiation under NE influence [18,27]. The third possible explanation of reduced pellet size
might be the acceleration of hypertrophy or the increase of matrix-degrading enzyme expression.
However, in contrast to NE-treated BMSC pellets, hypertrophic differentiation characterized by
increased COL10A1, RUNX2, and MMP13 expression was not observed in the present study [18].
One reason for suppressed hypertrophy might be the incubation of the pellets under physioxia as
recently described by others [29,40].
In order to confirm the involvement of the β2-AR, the only β-AR expressed by chondrogenic
pellets, specific AR antagonists were tested in combination with NE. Based on previous studies [18,27],
we expected that the β2-AR antagonist propranolol might reverse the NE-mediated inhibition of sASC
chondrogenesis. However, propranolol was only partly able to neutralize NE effects, while the α2-AR
antagonist yohimbine significantly abrogated the inhibitory effect of NE on the pellet volume and type
II collagen protein. The only existing study analyzing alpha-adrenergic signaling in chondrocytes was
performed by Jiao et. al. identifying α2a-AR as responsible AR for promoting degenerative remodeling
in the temporomandibular joint by induction of catabolic activities in chondrocytes [25]. Typically,
α2a-AR used to be targeted by lower NE concentrations such as 10−8 M [12], but in the present study
the effects of high NE concentrations were neutralized by α2a-AR and not or only partly by β2-AR.
The reason for these mixed α2-/β2-AR-mediated effects might be the instability of NE under cell culture
conditions, as demonstrated. After one or two days in culture medium, less than 40% of the initial
NE is still available, thus, the 10−7 M initial NE concentration might decrease to 10−8 M. Another
possible explanation would be the switch of β2-AR from Gαs to Gαi signaling as described previously
by us [41]. The fact that the α1-ARs were not involved in any effect was not surprising, since no studies
describing α1-AR-induced influences on chondrogenesis exist.
In conclusion, this study demonstrated that sASCs obtained from OA patients exhibit a strongly
decreased chondrogenic capacity in the presence of NE mediated by α2a-dependent ERK1/2
phosphorylation and reversed by the specific α2-AR antagonist yohimbine. Thus, NE might
suppress sASC-dependent regeneration of articular cartilage and contribute to the manifestation
of OA. Therefore, the inhibition of α2a-adrenergic signaling pathways represents a promising approach
for the development of novel OA strategies.
4. Materials and Methods
4.1. Patients
Adipose synovial tissue was obtained from patients with OA during knee joint replacement
surgery. The experimental cohort included 32 patients (characteristics of patients in Table 1). Patients
were informed about the purpose of the study and gave written consent. A non-selective beta blocker
medication, targeting not only β1- but also the β2-AR, was a criterion for exclusion in this study.
The project was approved by the Ethics Committee of the University of Regensburg (Ethikkommission
der Medizinischen Fakultät der Universität Regensburg, vote number/project ID 13-101-0135, approved:
26 August 2015) and of the Ethics Committee Goethe University Frankfurt am Main (Ethik-Kommission
des Fachbereichs Medizin Universitätsklinikum der Goethe-Universität, vote number/project ID
148-17B, approved: 10 May2017). All experiments were performed in accordance with relevant
guidelines and regulations.
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Table 1. Characteristics and medication of patients under study.
Characteristics Number/Mean/(%)/(Range)
total (number) 32
female/male (number, %) 12/20 (37.5%/62.5%)
age (years—mean ± stdd., (range)) 65.92 ± 9.84 (46–88)
C-reactive protein (mg/L) 1.48 ± 1.11
medication
non-steroidal antiinflammatory drugs 31 (97%)
steroids (other than prednisolone) n.a.
opioid analgesics 2 (6.25%)
biologicals n.a.
antihypertensive drugs 19 (59.3%)
non-selective beta blockers (β1 and β2) 0 (0%)
selective beta blockers (β1) 8 (25%)
other (AT1, ACE, CCB) 11 (34.4%)
Abbreviation: n.a.—not applicable, stdd.—standard deviation, AT1—angiotensin II type 1 receptor blockers,
ACE—Angiotensin converting enzyme (ACE) inhibitors, CCB—calcium channel blockers.
4.2. Isolation and FACS Characterization of Human ASCs
Human sASCs were isolated as described previously [42]. The cells were seeded in 75 cm2 tissue
culture flasks and cultivated in Dulbecco’s modified Eagle medium (DMEM/F12; Gibco Invitrogen,
Thermo Fisher Scientific, Darmstadt, Germany) containing 1% penicillin/streptomycin (Gibco
Invitrogen) and 10% MSC qualified FBS (Gibco Invitrogen) at 37 ◦C in a humidified atmosphere
containing 2% O2 and 5% CO2. The MSC characteristics of isolated sASCs were investigated by FACS
analysis according to the suggestions of “The Mesenchymal and Tissue Stem Cell Committee of the
International Society for Cellular Therapy” [34].
4.3. In Vitro Proliferation of sASC
Human synovial sASCs were seeded at a cell number of 2 × 105 in a 75 cm2 flask. In addition
to untreated control, cells were treated for 7 days with NE at different concentrations (10−9–10−6 M,
Sigma Aldrich, Munich, Germany) at 37 ◦C in a humidified atmosphere containing 2% O2 and 5%
CO2. NE was freshly added at day 0, 3, and 6. After seven days, total viable and dead cell number
was determined.
4.4. Determination of Cell Viability
To determine possible toxic effects of treatments lactate dehydrogenase release (LDH Cytotoxicity
Detection Kit; TaKara MK401, Shiga, Japan) was measured in supernatants of monolayer cell cultures
at day 7. In addition, LDH in supernatants during chondrogenesis at day 1, 7, 14, and 21 was
analyzed. Cells lysed with 1% Triton X-100 were taken as positive control and medium without cells as
negative control.
4.5. Chondrogenic Differentiation of sASCs
In vitro chondrogenesis was performed as described earlier [18,43] by using serum-free high
glucose DMEM containing 1% P/S, 100 nM dexamethasone, 200 µM ascorbate-2-phosphate, 10 ng/mL
TGF-β3, 10 ng/mL BMP-6 and ITS+3 premix (Sigma). Pellets (200.000 cells per pellet) were formed
by centrifugation (491× g) in 96-well plates with conical bottom (Nunc/Fisher Scientific, Schwerte,
Germany) and were cultivated for 21 days at 37 ◦C in a humidified atmosphere containing and 2% O2
and 5% CO2. Pellets were treated with NE (10−9–10−6 M, Sigma). In addition, pellets were treated with
specific α1-AR antagonist doxazosin (10−7 M, Tocris Bioscience, Bristol, UK), specific α2-AR antagonist
yohimbine (10−6 M, Tocris Bioscience), and specific β2-AR antagonist propranolol (10−6 M, Tocris
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Bioscience, Bristol, UK), alone or in combination with NE (10−6 M). The differentiation medium with
freshly diluted supplements was changed every two days.
4.6. Norepinephrine Quantification
The stability of NE at the cell culture conditions used was examined by adding a concentration
of 10−6 M NE to the culture medium at time point zero and high-pressure liquid chromatography of
medium samples after 24 h as previously described by us [44].
4.7. Western Blot Analysis
In order to examine whether monolayer chondrocytes respond to NE, the two major AR-dependent
signaling pathways—the phosphorylation of PKA and ERK1/2—were investigated. The sASCs were
treated with NE (10−9–10−6 M) and/or with specific AR antagonists as described previously [25].
ASCs were lysed and pellets were mechanically homogenized using Polytron PT-1200 (Kinematica,
Thermo Fisher Scientific, Darmstadt, Germany) homogenizer and proteins were isolated using
PhosphoSafe™ Extraction Reagent (Merck Millipore, Darmstadt, Germany). Samples were loaded onto
10% SDS-PAGE and electro-transferred to a polyvinylidene difluoride (PVDF) membrane. Membranes
were blocked with 5% bovine serum albumin for 1 h at room temperature before incubation with
primary antibodies detecting total ERK1/2 (#9107, mouse, Cell Signaling Technology, Frankfurt am
Main, Germany), phosphorylated ERK1/2 (#4370; rabbit, Cell Signaling Technology), total PKA
(ab32514, rabbit, Abcam, Cambridge, UK), phosphorylated PKA (ab32390, rabbit, Abcam) and GAPDH
(MA5-15738, mouse, Thermo Fisher Scientific, Darmstadt, Germany) at 4 ◦C overnight. The membranes
were incubated with a HRP-conjugated secondary antibody (swine anti-rabbit P039901-2, rabbit
anti-mouse P026002-2, both from DAKO, Agilent Technologies, Hamburg.Germany) for 1 h at room
temperature. The target protein was detected using the enhanced chemiluminescence (ECL, Thermo
Fisher Scientific, Darmstadt, Germany) reagents, with GAPDH as endogenous control. Densitometric
values of the detected bands were quantified using the ImageJ Software (https://imagej.nih.gov/ij/
download.html).
4.8. RNA Isolation, Endpoint and Real-Time Quantitative PCR
Monolayer sASCs were lysed and pellets were homogenized mechanically (Polytron PT-1200,
Kinematica). RNA isolation was performed using the NucleoSpin RNA kit (Machrey Nagel, Düren,
Germany) according to the manufacturer’s instructions. cDNA synthesis was carried out using qScript
cDNA Supermix (Quanta Biosciences, Beverly, MA, USA). Gene expression of α- (α1A, α1B, α1D, α2A,
α2B, α2C), β-AR (β1, β2, β3) subtypes and TH was determined by qPCR using Taq PCR Master Mix
kit (Qiagen, Hilden, Germany). The PCR products were run on a 1.8% (wt/vol) agarose gel, stained
with GelRed Nucleic Acid Gel Stain (Biotium, Fremont, CA, USA). Average score of AR and TH gene
expression in sASCs from three different OA patients was calculated. In order to analyze the effects of
NE and specific antagonists on chondrogenic differentiation of sASCs, real-time quantitative PCR was
performed using Quanta PerfeCta SYBR Green FastMix (Quanta Biosciences) in a qTOWER3 real time
PCR Thermocycler (Analaytik, Jena, Jena, Germany). Gene expression of chondrogenic markers (SOX9,
COL2A1), of fibrous cartilage markers (COL1A1), and hypertrophic markers (RUNX2,COL10A1,
and MMP13) was quantified. GAPDH served as endogenous control. Relative gene expression was
determined using qPCR software (Analytic, Jena). All primers were synthesized by Thermo Fisher
Scientific (Supplementary Table S1).
4.9. Macroscopic and Histological Investigations
Macroscopic images of day 7, 14, and 21 pellets were taken using a standard binocular with
Polaroid PDMC-3 camera. Surface areas of spherical pellets were analyzed (ImageJ software) and
the pellets volume was calculated mathematically using the average radius. Then, pellets were fixed
after day 7, 14, and 21 in 4% paraformaldehyde and infiltrated with increasing concentrations (10, 20,
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and 30%) of sucrose, each concentration for one day. Pellets were embedded in Tissue-Tek (Sakura,
Alphen aan den Rijn, Netherlands) and sectioned at 8 µm thickness using a cryotom ( Cryostar NX70,
Thermo Fisher Scientific, Darmstadt, Germany). Cryosections were stained with dimethylmethylene
blue (DMMB, Sigma Aldrich, Munich) to visualize the sulfated glycosaminoglycans (sGAGs).
4.10. Immunohistochemistry
After 5 min rehydration in 1× PBS, cryosections to be stained for adrenergic receptors were
demasked using citrate buffer (10 mM sodium citrate, 0.05% tween 20, pH 6) for 20 min at 95 ◦C.
Sections for type II collagen staining were digested with 1 mg/mL pepsin in 1× McIlvaine buffer (pH
3.6) for 12–15 min at 37 ◦C. Then endogenous alkaline phosphatase (Bloxall, Vector Labs, Linaris,
Dossenheim, Germany, 10 min, room temparature) peroxidase (0.3% H2O2 10 min, room temperature)
were blocked. Non-specific binding sites were blocked using secondary antibody-specific sera
(VECTASTAIN®ABC-AP Staining KIT, Vecor Labs, Linaris, Dossenheim, Germany or HRP-AEC Kit,
Linaris, Dossenheim, Germany) for 45 min at room temperature. Sections were then incubated with
the primary rabbit antibodies directed against α2a AR (1:200; ab85570), β2-AR (1:200; ab213651),
and type II collagen (1:200, ab34712) at 4 ◦C overnight. Specific staining was visualized using
horseradish peroxidase labelled secondary antibodies and ALP or peroxidase substrate solutions
(VECTASTAIN®ABC-AP Staining KIT, Vecor Labs, Linaris, Dossenheim, Germany or HRP-AEC Kit,
Linaris, Dossenheim, Germany).
4.11. Biochemical Analysis of sGAGs and Type II Collagen Protein
For the quantification of sGAGs and type II collagen levels as well as double-stranded DNA
(dsDNA), pellets were mechanically homogenized using a Polytron PT-1200 (Kinematica) homogenizer
and digested as described previously [18]. Concentration of dsDNA was determined using the
Quant-iT PicoGreen assay kit (Invitrogen). The sGAG content of digested pellets was measured using
a colorimetric assay based on dimethylmethylene blue (DMMB, Sigma) [18,42]. Type II collagen protein
levels were quantified by ELISA (Chondrex, AMS Biotechnology (Europe) Ltd, Abingdon OX14 4SE,
UK). sGAG and type II collagen levels were normalized to the dsDNA content.
4.12. Statistical Analysis
Statistical analysis was performed using SigmaPlot software (SigmaPlot V.13, Systat Software,
Erkrath, Germany). All experiments were carried out with cells of 4–10 patients. Comparisons
between groups were performed using ANOVA on ranks or Wilcoxon/Mann–Whitney-Test followed
by Bonferroni or Dunn’s correction. p values less than 0.05 were considered significant.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/20/13/
3127/s1.
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Abbreviations
ACE Angiotensin converting enzyme
AEC 3-Amino-9-ethylcarbazole
AP Alkaline phosphatase
AR Adrenoceptor
AT1 Angiotensin II type 1 receptor
BMP-6 Bone morphogenetic protein
BMSC Bone marrow-derived MSCs
cAMP Cyclic adenosine monophosphate
CCB Calcium channel blockers
CD Cluster of differentiation
cDNA Complementary desoxy ribonucleic acid
COL10A1 Collagen type X alpha 1 chain
COL1A1 Collagen type I alpha 1 chain
COL2A1 Collagen type II alpha 1 chain
DA Dopamine
DMEM/F12 Dulbecco’s modified eagle’s medium and Ham’s F-12 Medium
DMMB 1,9-Dimethyl-methylene blue
DPBS Dulbeccos phosphate-buffered saline
dsDNA Double stranded DNA
E Epinephrine
ECM Extracellular matrix
ELISA Enzyme-linked immunosorbent assay
ERK Extracellular signal-regulated kinases
FBS Fetal bovine serum
GAG Glycosaminoglycan
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
HLA-DR Human Leukocyte Antigen—DR isotype
HRP Horseradish peroxidase
ITS Insulin, human transferrin, and selenous acid
LDH Lactate dehydrogenase
MMP13 Matrix metallopeptidase 13
mRNA Messenger ribonucleic acid
MSC Mesenchymal stem cells
NE Norepinephrine
OA Osteoarthritis
P/S Penicillin streptomycin
PCR Polymerase chain reaction
PFA Paraformaldehyde
PKA Proteinkinase A
PVDF Polyvinylidene difluoride
RT-PCR Reverse-transcriptase PCR
RUNX2 Runt-related transcription factor 2
sASC Synovial adipose stem cell
SDS-Page Sodium dodecyl sulfate polyacrylamide gel electrophoresis
sGAG Sulphated Glycosaminoglycans
SOX9 SRY-box 9
TBST Tris buffered saline with Tween20
TGF-β Transforming growth factor β
TH Tyrosine hydroxylase
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